Brokerages Expect AnaptysBio Inc (ANAB) Will Post Quarterly Sales of $2.10 Million

Wall Street analysts expect that AnaptysBio Inc (NASDAQ:ANAB) will announce $2.10 million in sales for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for AnaptysBio’s earnings, with the highest sales estimate coming in at $2.30 million and the lowest estimate coming in at $2.00 million. The firm is expected to issue its next earnings report on Tuesday, February 6th.

According to Zacks, analysts expect that AnaptysBio will report full-year sales of $2.10 million for the current fiscal year, with estimates ranging from $7.00 million to $9.30 million. For the next fiscal year, analysts expect that the business will post sales of $11.66 million per share, with estimates ranging from $6.00 million to $22.80 million. Zacks’ sales averages are an average based on a survey of research analysts that that provide coverage for AnaptysBio.

AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.47) by $0.02.

A number of research analysts have issued reports on the company. Wedbush restated an “outperform” rating and issued a $75.00 price objective (up previously from $37.00) on shares of AnaptysBio in a research note on Friday, October 13th. Jefferies Group began coverage on AnaptysBio in a research note on Thursday, November 9th. They issued a “buy” rating and a $101.00 price objective for the company. JMP Securities increased their price target on AnaptysBio from $45.00 to $82.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 10th. Stifel Nicolaus reiterated a “buy” rating and set a $76.00 price target (up previously from $35.00) on shares of AnaptysBio in a research note on Friday, October 13th. Finally, Robert W. Baird set a $69.00 price target on AnaptysBio and gave the stock a “buy” rating in a research note on Wednesday, October 11th. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. AnaptysBio currently has a consensus rating of “Buy” and an average price target of $101.89.

AnaptysBio (NASDAQ ANAB) opened at $105.39 on Thursday. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 12 month low of $16.06 and a 12 month high of $126.23.

Several hedge funds have recently bought and sold shares of ANAB. Citadel Advisors LLC bought a new position in shares of AnaptysBio during the 3rd quarter worth $20,406,000. VHCP Management II LLC bought a new position in shares of AnaptysBio during the 3rd quarter worth $5,856,000. Kornitzer Capital Management Inc. KS bought a new position in shares of AnaptysBio during the 4th quarter worth $12,767,000. JPMorgan Chase & Co. grew its stake in shares of AnaptysBio by 210.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 183,319 shares of the biotechnology company’s stock worth $6,363,000 after acquiring an additional 124,219 shares during the period. Finally, Sphera Funds Management LTD. bought a new position in shares of AnaptysBio during the 3rd quarter worth $2,796,000. Institutional investors own 75.37% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2018/02/01/brokerages-expect-anaptysbio-inc-anab-will-post-quarterly-sales-of-2-10-million.html.

AnaptysBio Company Profile

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Get a free copy of the Zacks research report on AnaptysBio (ANAB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply